Literature DB >> 21670699

Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.

C Bethan Powell1, Lee-may Chen, Jane McLennan, Beth Crawford, Charles Zaloudek, Joseph T Rabban, Dan H Moore, John Ziegler.   

Abstract

BACKGROUND: Women carriers of BRCA mutations often have occult malignancy found at the time of risk-reducing bilateral salpingo-oophorectomy (RRSO). We report outcomes in 111 consecutive BRCA-positive women who had RRSO using a rigorous surgical-pathological protocol from 1996 to 2008.
METHOD: We identified risk factors associated with finding an occult malignancy at RRSO with outcomes followed for a median of 61 months.
RESULTS: A total of 111 BRCA carriers elected RRSO, 10 patients [9.1%] had 14 sites of occult neoplasia. Two patients had invasive serous fallopian tube carcinoma (TSC) only, 1 patient had invasive serous ovarian carcinoma (OSC) only, 5 patients had tubal intraepithelial carcinoma (TIC) only, and 2 patients had multifocal lesions of the ovary (OSC) and TIC. Occult ovarian carcinomas were only detected in BRCA1 patients, and all BRCA2 carcinomas involved only the fallopian tube. The odds of finding occult carcinoma is 4 times greater (odds ratio, 4.3; 95% confidence interval, 1.06-20.7) in women older than 50 than in younger ones (P=0.023). A history of invasive breast cancer was associated with a reduced risk of occult carcinoma (odds ratio, 0.2; 95% confidence interval, 0.05-0.85). In median follow-up of 5 years, recurrence rate after detection of an occult carcinoma was 10% and the risk for primary peritoneal carcinoma was less than 1%.
CONCLUSION: A rigorous surgical protocol with meticulous pathologic review at RRSO yielded an overall detection rate of 9.1% for occult gynecological carcinoma in BRCA mutation carriers followed by a multidisciplinary team at a single institution. Primary peritoneal carcinoma after RRSO is rare.

Entities:  

Mesh:

Year:  2011        PMID: 21670699     DOI: 10.1097/IGC.0b013e31821bc7e3

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  40 in total

1.  Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas.

Authors:  Wenxin Zheng; Oluwole Fadare
Journal:  Int J Clin Exp Pathol       Date:  2012-03-25

2.  Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Phuong L Mai; Marion Piedmonte; Paul K Han; Richard P Moser; Joan L Walker; Gustavo Rodriguez; John Boggess; Thomas J Rutherford; Oliver Zivanovic; David E Cohn; J Tate Thigpen; Robert M Wenham; Michael L Friedlander; Chad A Hamilton; Jamie Bakkum-Gamez; Alexander B Olawaiye; Martee L Hensley; Mark H Greene; Helen Q Huang; Lari Wenzel
Journal:  Gynecol Oncol       Date:  2017-02-10       Impact factor: 5.482

3.  Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study.

Authors:  L Minig; S Cabrera; R Oliver; A Couso; M J Rubio; S Iacoponi; M B Martin-Salamanca; S Carballo-Rastrilla; J M Cádenas-Rebollo; A García-Garcia; B Gil-Ibáñez; M J Juan-Fita; M G Patrono
Journal:  Clin Transl Oncol       Date:  2018-04-05       Impact factor: 3.405

4.  Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC).

Authors:  Stephanie L Wethington; Kay J Park; Robert A Soslow; Noah D Kauff; Carol L Brown; Fanny Dao; Ebunoluwa Otegbeye; Yukio Sonoda; Nadeem R Abu-Rustum; Richard R Barakat; Douglas A Levine; Ginger J Gardner
Journal:  Int J Gynecol Cancer       Date:  2013-11       Impact factor: 3.437

5.  Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals.

Authors:  Terri Febbraro; Katina Robison; Jennifer Scalia Wilbur; Jessica Laprise; Amy Bregar; Vrishali Lopes; Robert Legare; Ashley Stuckey
Journal:  Gynecol Oncol       Date:  2015-04-28       Impact factor: 5.482

6.  Should Fallopian Tubes Be Removed During Hysterectomy Procedures? - A Statement by AGO Ovar.

Authors:  M Pölcher; S Hauptmann; C Fotopoulou; B Schmalfeldt; I Meinhold-Heerlein; A Mustea; I Runnebaum; J Sehouli
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-04       Impact factor: 2.915

Review 7.  Precursors of ovarian cancer in the fallopian tube: serous tubal intraepithelial carcinoma--an update.

Authors:  Felix Zeppernick; Ivo Meinhold-Heerlein; Ie-Ming Shih
Journal:  J Obstet Gynaecol Res       Date:  2014-10-20       Impact factor: 1.730

Review 8.  Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act.

Authors:  Roi Tschernichovsky; Annekathryn Goodman
Journal:  Oncologist       Date:  2017-03-17

9.  Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.

Authors:  C B Powell; E M Swisher; I Cass; J McLennan; B Norquist; R L Garcia; J Lester; B Y Karlan; L Chen
Journal:  Gynecol Oncol       Date:  2013-02-04       Impact factor: 5.482

10.  Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices.

Authors:  Goli Samimi; Britton Trabert; Máire A Duggan; Jennifer L Robinson; Kisha I Coa; Elizabeth Waibel; Edna Garcia; Lori M Minasian; Mark E Sherman
Journal:  Gynecol Oncol       Date:  2018-03       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.